GLP-1 injections: Are compounded semaglutide needle claims accurate?

What did @pepfit.longevity actually say?

The creator held up a small insulin-style needle and made two core arguments: compounded semaglutide and tirzepatide require self-injection, but the needle is "teeny, teeny, tiny" and essentially painless because it's the same type diabetics use for daily insulin. They also mentioned their compounded formulation includes B12 "to offset a lot of your symptoms," and that patients draw their own doses from a vial rather than using a pre-filled pen like Ozempic or Mounjaro.

They pushed back on needle anxiety by reasoning that diabetics "would not inject themselves every single day if the needle was hurtful or painful." They also offered in-office training for first injections. On the surface, this is a needle-fear-reduction video. But there are real accuracy questions buried in the claims.

Does the science back this up?

On needle size, yes, largely. The claim holds up reasonably well. GLP-1 injections typically use 4-6mm, 31-32 gauge needles, which are the same gauge range used in insulin delivery. A 2016 study by Hirsch et al. in Diabetes Technology and Therapeutics confirmed that shorter, finer needles produce equivalent insulin delivery with significantly less pain and anxiety. The logic transfers to GLP-1 administration.

The once-weekly dosing claim for both semaglutide and tirzepatide is accurate. Both FDA-approved brand versions and compounded analogs are dosed weekly. That part is straightforward.

The B12 claim is where the science gets thin fast. There is no peer-reviewed evidence establishing that adding B12 to a compounded GLP-1 formulation meaningfully reduces side effects like nausea, fatigue, or GI distress. The creator presents this as settled practice. It is not. GLP-1-associated nausea is primarily mediated by central nervous system receptors and gut motility changes, not by a B12 deficiency that B12 supplementation would correct.

What did they get wrong (or right)?

They got the needle comparison mostly right. Credit where it's due: insulin pen needles are genuinely among the least painful injection formats available, and the psychological parallel is reasonable for patients with needle anxiety.

They got the B12 claim wrong, or at minimum unsupported. Describing it as something that offsets "a lot of your symptoms" implies clinical efficacy that hasn't been demonstrated in controlled trials. This is a marketing claim dressed up as pharmacology. A compounding pharmacy adding B12 to a GLP-1 formulation is not the same as a studied adjunct therapy.

They also blurred the line between compounded and brand-name drugs in a way that warrants scrutiny. Saying "Mounjaro and Ozempic come in a pre-filled syringe, ours comes in a vial" frames these as equivalent products with different packaging. They are not equivalent. Compounded semaglutide and tirzepatide are not FDA-approved and have not undergone the same manufacturing, stability, or bioequivalence testing as brand versions. The FDA issued warnings about compounded GLP-1 products in 2024 specifically because of patient safety reports.

What should you actually know?

If needle anxiety is your barrier to GLP-1 therapy, the creator's reassurance about needle size is reasonable. A 31-gauge, 4mm needle is genuinely small. Studies support the idea that fine-gauge needles cause minimal pain during subcutaneous injection.

But do not take the B12 adjunct claim at face value. Ask your prescriber for the clinical rationale and whether there is any published evidence supporting it in this specific context. "We add it to offset symptoms" is not a clinical answer.

More importantly, if you are considering compounded GLP-1 products, understand what you are choosing. The FDA placed compounded semaglutide on its list of drugs with demonstrated shortage in 2023-2024, which created a legal window for compounding. But as of early 2025, FDA has signaled that window is closing, and it has flagged safety concerns including dosing errors and contamination risks with some compounded versions. This does not mean compounded GLP-1 drugs are universally dangerous, but it does mean they require a different level of due diligence than a brand-name, FDA-approved product.

• Always confirm your compounding pharmacy is 503A or 503B accredited.
• Ask specifically what testing the compounded product has undergone for potency and sterility.
• Do not assume compounded equals equivalent to brand.